1. Introduction {#sec1}
===============

Paranasal sinus cancer represents a small portion of the head and neck cancer, approximately 5% of all head and neck tumors \[[@B1]\]. These tumors may arise from multiple tissues present in the nose and paranasal sinuses \[[@B2]\] or more rarely be a metastasis from a distant primary cancer.

Prostate adenocarcinoma is the most prevalent malignant cancer in the male population. In Europe, the incidence rate is 214 cases per 1000 men \[[@B3]\]. Metastases from prostate tumors are a major determinant of survival rates, and prostate-specific antigen tests decrease the incidence of metastatic disease at diagnosis \[[@B4]\].

In this article, we presented the rare case of a patient with a distant metastasis in the right ethmoid cells from a prostate adenocarcinoma.

2. Case Report {#sec2}
==============

A 58-year-old male patient was referred to the Otolaryngology Emergency Service because of important unilateral epistaxis, the third episode in the previous month. He also presented with ipsilateral nasal obstruction and diplopia with a three-month evolution. In his medical report, there was a record of penile squamous cell carcinoma treated with surgery and radiotherapy in 2014 and stage IV prostate adenocarcinoma (iliac, lumbar, and encephalic metastasis) refractory to hormone therapy and chemotherapy, submitted to palliative radiotherapy one month earlier.

During endoscopy, a polypoid, papilloma-like mass originated from the middle meatus was visible, occupying the entire right nasal fossa. No other abnormality was seen in the left nasal fossa. The epistaxis was controlled; the patient was stabilized and referred to biopsy.

The computed tomography (CT) and magnetic resonance imaging (MRI) showed soft tissue density lesion in the right nasal fossa, ethmoid cells, and maxillary sinus with extension into the inferior portion of the orbit through the lamina papyracea and posteriorly to the pterygomaxillary fissure (Figures [1](#fig1){ref-type="fig"} and [2](#fig2){ref-type="fig"}).

The biopsy resulted in adenocarcinoma (Figures [3(a)](#fig3){ref-type="fig"} and [3(b)](#fig3){ref-type="fig"}). Since the patient had a medical report of prostate adenocarcinoma, the sample was submitted to an immunohistochemical panel. The prostate-specific antigen (PSA) was highly positive, and the diagnosis was confirmed as metastatic prostate adenocarcinoma (Figures [4(a)](#fig4){ref-type="fig"} and [4(b)](#fig4){ref-type="fig"}).

Because of the clinical status of the patient, a few symptoms presented, and the fact that he was already submitted to radiotherapy at the same field, it was opted for a clinical follow-up. After two months of the diagnosis, the patient deceased.

3. Discussion {#sec3}
=============

Paranasal sinuses are a complex anatomic area, surrounding important structures such as the orbit and skull base. The most incident tumors are the squamous cell carcinoma, followed by adenocarcinoma and adenoid cystic carcinoma \[[@B5]\].

In a review, Prescher and Brors reported 169 cases of metastatic tumor to the paranasal sinuses \[[@B6]\]. Most cases originated from the kidney, followed by the lung, breast, thyroid, and prostate. Prescher and Brors also reported that the maxillary sinus was the most affected, followed by the sphenoid, ethmoid, and frontal sinuses \[[@B6]\]. These data are similar to those published by Bernstein \[[@B7]\]. In 77% of the cases, just one paranasal sinus was affected \[[@B6]\].

The nonspecific symptoms are similar to those of primary tumors. The nasal symptoms are usually nasal mass, nasal obstruction, facial deformity, and epistaxis. Orbital symptoms may also occur, such as proptosis, ptosis, decreased vision, and diplopia. Occasionally, these symptoms may be the first presentation of an occult primary tumor \[[@B8], [@B9]\].

The most frequent sites involved in prostate metastasis are the bone (90%), lung (46%), and liver (25%) \[[@B10]\]. The head and neck are rare locations for metastasis, and it occurs more frequently in the brain, dura, and lymph nodes \[[@B11]\]. The treatment may be hormone therapy, chemotherapy, radioisotopes, and radiotherapy \[[@B12]\].

Metastasis may reach the paranasal sinuses by hematogenous, lymphogenous, or vertebral venous plexus pathways. First postulated by Batson \[[@B13]\], this low-pressure valveless system is a connection between deep pelvic veins, intercostal veins, vena cava, and the azygos system. A rise in the abdominal pressure might redirect the blood flux from the vena cava system to the vertebral venous plexus. This flux alteration can allow the tumor to reach the paranasal sinuses \[[@B14]\].

This is the twenty-fifth reported case of metastatic prostate adenocarcinoma in the paranasal sinuses. The majority of cases involved patients with known prostate cancer, with a mean age of 63.15 years, and the most affected sinus was the sphenoid (44.5%). Radiotherapy was the preferred treatment option (40.7%). In [Table 1](#tab1){ref-type="table"}, we describe the cases reported in full text, available online so far.

Imaging is not able to differentiate a local tumor from a metastasis; however, it is essential to determine location and extension and for surgical planning. CT may show enhancement, bone erosion, remodeling, and invasion. Magnetic resonance imaging (MRI) has an important role to help, defining leptomeningeal and orbital invasion \[[@B13]\]. Positron emission tomography (PET-CT) might be useful in the primary occult tumor.

Histopathology has an essential role in the diagnosis. When metastasizing to the paranasal sinuses, normally prostate carcinoma is not well differentiated. Immunohistochemical panel is also important, with positivity of prostate-specific antigen, prostate acid phosphatase, EpCam, NKX3.1, and prostein \[[@B36]\].

Usually, the diagnosis of a metastasis to the paranasal sinuses means a poor prognosis. An important factor that can be crucial is whether the metastasis is isolated or part of a widespread disease.

Normally, the treatment involving the metastasis to the paranasal sinuses is palliative, with the exception of an isolated metastasis, for which the radical surgery may be a viable option. The patient\'s quality of life should be a priority. The main goal is pain relief and bleeding prevention. Management has not changed greatly over the years, and therapy options include radiotherapy, chemotherapy, immunotherapy, and, more recently, endoscopic surgery \[[@B37]\].

Endoscopic surgery may provide symptom relief faster, with lower systemic and local side effects \[[@B37]\]. Tabaee et al. suggested three criteria to help in the decision of the surgery: reasonable expectation of improvement, possible prolongation of life, and survivability after anesthesia \[[@B38]\].

4. Conclusion {#sec4}
=============

Despite being a rare entity, metastatic prostatic tumor in the paranasal sinuses should always be part of the differential diagnosis in patients with known prostatic tumor and recently developed nasal or orbital symptoms.
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![CT demonstrates lesion occupying ethmoid cells, nasal cavity, and maxillary sinus and extending through the lamina papyracea.](CRIOT2018-5428975.001){#fig1}

![T1-weighted MRI with fat suppression demonstrates the lesion extending to the pterigomaxillary fissure.](CRIOT2018-5428975.002){#fig2}

![(a) Neoplasia infiltrating surrounding tissue with irregular margins (H&E stain). (b) Atypical epithelial islands with ductal characteristics resembling adenocarcinoma (H&E stain).](CRIOT2018-5428975.003){#fig3}

![(a) Positive reaction to the PSA antigen in the epithelial islands, and there is no reaction in the superficial epithelium. (b) Strong expression of the PSA antigen in the ductal cells.](CRIOT2018-5428975.004){#fig4}

###### 

Prostate metastasis to the paranasal sinuses.

  Author                            Age   Sinus                             Symptoms                                                                             Treatment                         Survival
  --------------------------------- ----- --------------------------------- ------------------------------------------------------------------------------------ --------------------------------- --------------------------------------------------
  Barrs et al. \[[@B15]\]           61    Sphenoid                          Diplopia                                                                             Unknown                           Died 2 years after presentation
  Barrs et al. \[[@B15]\]           57    Sphenoid                          Diplopia, decreased visual acuity, ptosis, and numbness of the left face             Unknown                           Died 2 years after presentation
  McClatchey et al. \[[@B16]\]      54    Sphenoid                          Frontal headache and blurring of the right eye                                       Radiotherapy                      Alive 1 year after presentation
  Leduc et al. \[[@B17]\]           75    Sphenoid                          Diplopia and ptosis of the right eye                                                 Pulpectomy                        Alive 19 months after presentation
  Matsumoto et al. \[[@B18]\]       79    Sphenoid                          Headache and diplopia                                                                Orchiectomy                       Unknown
  Har-el et al. \[[@B19]\]          77    Maxillary                         Exophthalmos of the right eye                                                        Orchiectomy and hormonal block    Unknown
  Mickel and Zimmerman \[[@B20]\]   67    Sphenoid                          Diplopia and numbness on the right side of the nose                                  Radiotherapy                      Died 2 and a half months after presentation
  Saleh et al. \[[@B21]\]           71    Sphenoid                          Bilateral exophthalmos and hemoptysis                                                None                              Died 1 month after biopsy
  Fortson et al. \[[@B22]\]         50    Ethmoid                           Nasal obstruction, diplopia, proptosis, and blurred vision                           Chemotherapy and radiotherapy     Died 7 months after presentation
  Telera et al. \[[@B23]\]          61    Sphenoid                          Ptosis and diplopia of the right eye                                                 Radiotherapy                      Died 13 months after presentation
  Oliver et al. \[[@B8]\]           72    Maxillary, frontal, and ethmoid   Frontal headache and retro-orbital pain                                              Hormonal block                    Alive three months after presentation
  Hunt et al. \[[@B11]\]            76    Sphenoid                          Unknown                                                                              Radiotherapy and hormonal block   Alive 14 months after presentation
  Lavasani et al. \[[@B24]\]        67    Sphenoid                          Decreased visual acuity                                                              Radiotherapy                      Alive 6 months after presentation
  Başeskioglu et al. \[[@B25]\]     69    Maxillary                         Sinus fullness                                                                       Radiotherapy                      Died 32 months after diagnosis
  Ibarguren et al. \[[@B26]\]       64    Maxillary and frontal             Ptosis, proptosis, and facial numbness                                               Hormonal block and chemotherapy   Alive 8 months after presentation
  El Khatib et al. \[[@B27]\]       57    Maxillary                         Facial swelling                                                                      Pulpectomy and hormonal block     Died 9 months after presentation
  Viswanatha \[[@B28]\]             68    Ethmoid and frontal               Facial swelling and epistaxis                                                        Radiotherapy                      Lost to follow-up after 3 months of presentation
  Tunio et al. \[[@B29]\]           65    Ethmoid                           Nasal obstruction, diplopia, and proptosis                                           Radiotherapy and hormonal block   Alive until article publication
  Azarpira et al. \[[@B30]\]        74    Maxillary                         Nasal obstruction                                                                    Chemotherapy and radiotherapy     Died 11 months after presentation
  Petersson et al. \[[@B31]\]       55    Sphenoid                          Headache, diplopia, and blurred vision                                               Hormonal block                    Unknown
  Puche-Sanz et al. \[[@B32]\]      56    Sphenoid                          Decreased visual acuity and facial numbness                                          Radiotherapy and hormonal block   Alive 5 years after presentation
  Akdemir et al. \[[@B33]\]         73    Frontal and ethmoid               Headache and exophthalmos                                                            Hormonal block                    Unknown
  Evarts et al. \[[@B34]\]          59    Maxillary and ethmoid             Cheek numbness, headache, decreased visual acuity, nasal obstruction, and drainage   Chemotherapy                      Died 2 months after biopsy
  Lechien et al. \[[@B35]\]         67    Frontal                           Diplopia, facial pain, and headache                                                  Hormonal block                    Died a few months after presentation
  Present case                      58    Ethmoid and maxillary             Epistaxis, nasal obstruction, and diplopia                                           None                              Died 2 months after diagnosis
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